Tildrakizumab Controls Psoriasis in Difficult-to-Treat Areas
- A study of 183 adult patients shows tildrakizumab, at both 100 mg and 200 mg dosages, resulted in high and sustained clinical responses for moderate-to-severe psoriasis through week...
- Tildrakizumab is a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), a key cytokine driving the inflammatory pathways in psoriasis.
- Researchers evaluated 183 adult patients with moderate-to-severe psoriasis who received either 100 mg (n=89) or 200 mg (n=94) of tildrakizumab.
Tildrakizumab (Ilumya; Sun Pharma) demonstrated sustained disease control in a real-world cohort of patients with moderate-to-severe psoriasis affecting difficult-to-treat anatomical areas, including the scalp, genital region, nails, adn palmoplantar surfaces-sites often associated with higher symptom burden and poorer treatment response, according to a recent study.
Tildrakizumab Demonstrates High Efficacy in Psoriasis Treatment
Table of Contents
A study of 183 adult patients shows tildrakizumab, at both 100 mg and 200 mg dosages, resulted in high and sustained clinical responses for moderate-to-severe psoriasis through week 104.
What is Tildrakizumab?
Tildrakizumab is a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), a key cytokine driving the inflammatory pathways in psoriasis. It’s approved for the treatment of moderate-to-severe plaque psoriasis.
Study Details and Patient Population
Researchers evaluated 183 adult patients with moderate-to-severe psoriasis who received either 100 mg (n=89) or 200 mg (n=94) of tildrakizumab. The study assessed outcomes up to week 104. Patients receiving the 200 mg dose were more likely to have a higher body mass index (BMI) or prior exposure to biologic therapies.
Key Findings: PASI Scores
The study demonstrated significant improvements in psoriasis severity as measured by the Psoriasis Area and Severity Index (PASI). By week 104:
- PASI75 (75% enhancement): 94.2% of patients on 100 mg and 94.7% on 200 mg achieved this benchmark.
- PASI90 (90% improvement): 82.7% of patients on 100 mg and 57.9% on 200 mg reached PASI90.
- PASI100 (Complete Clearance): 48.1% of patients on 100 mg and 47.4% on 200 mg experienced complete skin clearance.
Response Variations by Anatomical Site
improvements were observed across all difficult-to-treat areas, but the speed and extent of clearance varied. According to the Physician’s Global Assessment (PGA) scores, scalp and genital psoriasis showed earlier and more noticeable improvement compared to nail and palmoplantar psoriasis.